Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: Response assessment and imaging biomarkers

Francesca Maines, Orazio Caffo, Davide Donner, Isabella Sperduti, Emilio Bria, Antonello Veccia, Franca Chierichetti, Giampaolo Tortora, Enzo Galligioni

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: High rate of non-target lesions in metastatic castration-resistant prostate cancer usually limits applicability of Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and this has led to a growing interest in using PET/computed tomography (CT). We prospectively investigated the role of 18F-choline (FCH)-PET/CT in patients receiving enzalutamide after docetaxel. Patients & methods: 30 patients were monitored by means of FCH-PET/CT before and during the treatment. A Cox proportional hazards regression model was used to assess the associations between metabolic parameters and clinical outcomes. Results: Univariate analysis showed no significant correlation between biochemical and FCH-PET responses. Multivariate analysis showed that only baseline maximum standardized uptake value (SUVmax) significantly correlated with biochemical progression-free survival, radiological progression-free survival and overall survival. Conclusion: Our findings suggest that FCH-PET/CT may play a role in defining prognosis of patients receiving enzalutamide because baseline SUVmax proved to be an independent prognostic factor.

Original languageEnglish
Pages (from-to)333-342
Number of pages10
JournalFuture Oncology
Volume12
Issue number3
DOIs
Publication statusPublished - Feb 1 2016

Keywords

  • 18F-choline PET
  • castration-resistant prostate cancer
  • enzalutamide
  • response

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Serial <sup>18</sup>F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: Response assessment and imaging biomarkers'. Together they form a unique fingerprint.

Cite this